|
|
 |
November 27, 2007 |
Now Available: Download the podcast of Dr. Epstein's video presentation
With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
MSK Video Report:
Hot Topics in Osteoporosis
Sol Epstein presents Hot Topics in Osteoporosis: Osteonecrosis of the
Jaw, Bisphosphonate 'Drug Holidays,'
and Male Osteoporosis...
CME News: Teriparatide Builds More Bone Than Alendronate in Steroid-Caused Osteoporosis
Teriparatide built more bone mass and prevented more vertebral fractures than alendronate in the first head-to-head study of the two drugs for glucocorticoid-induced osteoporosis...
ACR 2007: Abatacept Wins Plaudits in Refractory JIA
The costimulation blocker abatacept may be a safe and effective option for juvenile idiopathic arthritis patients who have exhausted all other therapies...
ACR 2007: Researchers "Shocked" at Enbrel's Efficacy in JRA
Etanercept (Enbrel) is safe and effective in the long-term treatment of juvenile rheumatoid arthritis (JRA), according to new 8-year outcome data...
Arthritis: Combining MTX or Other DMARD With Biologic Seen as Best Strategy for MTX-Resistant Rheumatoid Arthritis
A systematic review of head-to-head trials and prospective cohort studies found little difference among either conventional DMARDs or anti-tumor necrosis factor (anti-TNF) drugs used as monotherapy, but suggests that adding a conventional DMARD to a biologic may be the best strategy for MTX-resistant RA...
BioPharm Business: Elan, Biogen Idec Report that CHMP Adopts Negative Opinion on Appeal of EU Application for Natalizumab (Tysabri) to Treat Crohn's
Elan Corp, plc and Biogen Idec announced that the Committee for Medicinal Products for Human Use has adopted a negative opinion on the marketing authorization for natalizumab (Tysabri) as a treatment for moderate-to-severe, active Crohn's disease (CD) in patients who had an inadequate response to or could not take conventional treatments and who have evidence of active inflammation...